share_log

BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target

Benzinga ·  04:46  · Ratings

BTIG analyst Julian Harrison upgrades Aclaris Therapeutics (NASDAQ:ACRS) from Neutral to Buy and announces $8 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment